Wechselwirkungen · Entresto
Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-134364 · Präparat HOS-097566
OATP1B1 and OATP1B3 substrates, e.g. statins In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. Entresto may therefore increase the systemic exposure of OATP1B1 and OATP1B3 substrates such as statins. Co-administration of sacubitril/valsartan increased the Cmax of atorvastatin and its metabolites by up to 2-fold and AUC by up to 1.3-fold. Caution should be exercised when co-administering sacubitril/valsartan with statins. No clinically relevant interaction was observed when simvastatin and Entresto were co-administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-13T10:33:00Z · SHA-256 63effd0dd78bf1b11f8cfe5ae77efc68b2653de13ba467bbf4e48289e340b97e · Passage d9a8627f1c7485b763a4614e14160a3a1a2d3d468d60abcdbba4513de2a84c4d · Zeichen 1395–1951 im Abschnitt